Zanamivir: Difference between revisions
| Line 10: | Line 10: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===[[Influenza]]=== | |||
*>7 years old: 10mg inhaled orally BID | *>7 years old: 10mg inhaled orally BID | ||
Latest revision as of 21:38, 10 March 2020
Administration
- Type: Antiviral
- Dosage Forms:
- Routes of Administration: Inhalation
- Common Trade Names:
Adult Dosing
Influenza
- 10 mg inhaled orally BID x 5 days
Pediatric Dosing
Influenza
- >7 years old: 10mg inhaled orally BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- Not recommended in patients with underlying respiratory disease
Adverse Reactions
Serious
- Dysrhythmia
- Seizure
- Delirium, abnormal behavior
- Bronchospasm
- Oropharyngeal edema
- Rash
Common
- Cough, nasal symptoms, throat pain
- Fever
Pharmacology
- Half-life: 2.5-5.1h
- Metabolism:
- Excretion: Renal, fecal
Mechanism of Action
- Inhibits neuroaminidase of influenza A and B, altering viral aggregation and release